Authors
John Webb, Mayra E Guerrero, Kamran I Muhammad, Adam B Greenbaum, Alejandro Vasquez, J Bradley Oldemeyer, Thom G Dahle, Brian P O'Neill, Charanjit Rihal, Michael Morse, Evelio Rodriguez, Mark Russo, Raj R Makkar, Brian Whisenant, Pradeep Yadav, Vinod Thourani, Ignacio Inglessis-Azuaje, Nathaniel Langer, Samir Kapadia, Curtiss Stinis, Matthew Price, Matthew Summers, Bassem M Chehab, Brett Grizzell, Jason Foerst, Ricardo Yaryura, Jorge Castellanos, John Wang, George Zorn, Peter Tadros, Oluseun Alli, Daniel Pu, Santiago Garcia, Michael J Mullen, Robert Boone, Philipp Blanke, Michael Pham, David A Baran, Federico M Asch, David V Daniels, ENCIRCLE trial Investigators
Published in
Journal of the American College of Cardiology. Nov 03, 2026. Epub Nov 03, 2026.
Abstract
Transcatheter mitral valve replacement (TMVR) is an approved treatment option for select high-risk patients with symptomatic mitral regurgitation (MR). The main cohort of the ENCIRCLE trial, evaluating fully percutaneous transseptal TMVR with the SAPIEN M3 system, demonstrated 13.9% mortality, significant MR reduction, and improved functional and health status outcomes at 1 year.
We report 2-year outcomes from the main cohort of the ENCIRCLE trial.
Eligible symptomatic patients with ≥3+ MR who were not suitable for surgery or transcatheter edge-to-edge repair underwent TMVR with the SAPIEN M3 system. Independent study oversight included an echocardiographic core laboratory and a clinical events committee. Endpoints included the nonhierarchical composite rate of all-cause mortality or heart failure hospitalization (HFH) as well as clinical, echocardiographic, functional, and health status outcomes.
A total of 299 patients were treated, with 2-year follow-up data available for 202 of 210 eligible patients (96.2%). Mean age was 75.5 ± 9.3 years, 50.8% were men, and the mean Society of Thoracic Surgeons Predicted Risk of Mortality score for mitral valve replacement was 6.6% ± 4.1%. At 2 years, MR reduction was sustained, with MR ≤1+ in 97.0% patients (P < 0.001). The 2-year composite rate of all-cause mortality or HFH was 35.6% (25.1% all-cause mortality, 23.0% HFH). In a 365-day landmark analysis, 1- to 2-year rates were 13.0% for all-cause mortality and 10.6% for first HFH. At 2 years, the rates of disabling stroke, clinically significant valve thrombosis, and hemolysis requiring intervention were 6.6%, 7.1%, and 7.6%, respectively. There were no instances of clinically significant left ventricular outflow obstruction. Improvements in functional and health status outcomes were sustained with 87.0% of patients in NYHA functional class I/II (P < 0.001) and a mean Kansas City Cardiomyopathy Questionnaire overall summary score increase of 17.2 points (P < 0.001). The 6-minute walk distance increased by +9.0 ± 97.3 m compared to baseline (P = 0.246).
The 2-year results of the ENCIRCLE trial demonstrated durable near MR elimination with sustained improvements in functional and health status outcomes in surviving patients. These findings support transseptal TMVR as a therapeutic option for carefully selected patients with symptomatic MR. (The ENCIRCLE Trial [ENCIRCLE]; NCT04153292).
PMID:
42980633
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 13
- Comments 0